Iowa Senate Bill SF2158

Iowa 2025-2026 Regular Session

• Introduced: 1/29/26
• Refer: 1/29/26

Caption

A bill for an act relating to the inspection of compounding pharmacies, and making penalties applicable.

Summary

SF 2158 creates a new inspection-and-remediation process for Iowa compounding facilities that prepare nonsterile pharmaceutical products. If a board of pharmacy inspector finds a facility out of compliance with USP General Chapter 795, the inspector must first notify the pharmacist in charge of the infraction. If the problem remains unresolved at a later inspection, the inspector must provide comprehensive instruction on how to correct it, and if it still is not corrected after a third inspection, the inspector must require mandatory education for the pharmacist in charge. The bill also authorizes the board to impose a single fine of up to $500, adjusted for inflation, if the facility fails to correct the infraction after the required steps. It limits the board to that one fine and bars other administrative fines or remedies under this section, while preserving any civil liability that may exist under tort, contract, or other law. In addition, it makes records related to the investigation and remediation of these infractions confidential and exempt from public examination.

Impact

The bill would add a new section to Iowa Code chapter 155A governing compounding facilities and would amend the state’s public-records law to exempt records tied to investigations and remediation of nonsterile compounding infractions. It gives the Iowa Board of Pharmacy a structured enforcement ladder—notice, instruction, mandatory education, and then a capped fine—while restricting the board from imposing additional penalties under this provision. The affected parties are compounding pharmacies, pharmacists in charge, the Board of Pharmacy, and members of the public seeking access to related enforcement records.

Sentiment

Based on the bill text and available legislative context, the measure appears to be a regulatory compliance bill rather than a highly partisan proposal. Its approach is corrective and educational first, with a relatively modest penalty only after repeated noncompliance, suggesting an intent to improve pharmacy practices without imposing harsh sanctions. No committee transcript or recorded votes were provided, so there is no evidence of formal opposition or support beyond the bill’s introduction and referral to subcommittee.

Contention

The main points of potential contention are the confidentiality provision and the limit on enforcement penalties. Pharmacy operators may favor the bill’s graduated compliance approach and capped fine, while transparency advocates could object to shielding investigation and remediation records from public access. Regulators or patient-safety advocates might also question whether a single $500 fine is sufficient to deter repeated noncompliance, whereas the bill’s supporters would likely view the education-first model as a balanced way to correct violations without over-penalizing facilities.